Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Analysis of cancer-specific urinary exosomal miRNA derived from urothelial carcinoma

Funder: Japan Society for the Promotion of Science

Funding period
JPY 3.9 M
USD 34 K
Funding amount
Abstract
Exosomes were extracted from urine of 6 urothelial carcinoma (UC) patients and 3 healthy volunteers by ultracentrifugation, and miRNA from urinary Exosomes was analyzed by miRNA array. We identified 5 miRNAs (miR-155-5p, miR-15a-5p, miR-21-5p, miR-132-3p and miR-31-5p) overexpressed in urinary exosomes of UC patients from miRNA microarray analysis.Five candidate miRNAs were all significantly expressed more highly in urinary exosomes of UC patients compared to those of the control in verification cohort (N=60, all P<0.0001). Of the 5 miRNAs, miR-21-5p in urinary exosomes was the most potent biomarker, having a sensitivity of 75.0%, specificity of 95.8%. This result was better than that of urine cytology in this cohort.
Similar projects All >
Sorted by: Start Date
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Next generation sequencing to enhance initial staging and dynamically monitor disease response in upper tract urothelial carcinoma

Bladder Cancer Advocacy Network to Philip Hilmi Abbosh, Wafik El-Deiry, Elizabeth Plimack

USD 50,000
2018 - 2020
Project list item
[Molecular mechanism of bladder cancer invasion and metastasis focusing on invadopodia, exosome, and hyaluronidase] - Original in Japanese

Japan Society for the Promotion of Science to 範子 得居

USD 38,114
2018 - 2021
Project list item
Discovery of novel urinary biomarker of bladder cancer by proteomic analysis of urinary and tissue-exudative exosomes.

Japan Society for the Promotion of Science to Kyosuke Matsuzaki

USD 35,167
2017 - 2019

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies